[Ovum donation: a 3-year experience at the Gynecologic and Obstetric Center of Monterrey, Mexico]. / Donación de óvulos: experiencia de tres años en el Centro de Ginecología y Obstetricia de Monterrey.

OBJECTIVE: Evaluating the rate of pregnancies, neonates, implantation rate and kinds of donor in our program Assisted Reproduction with oocyte donation. INTRODUCTION: The oocyte donation is the most important support in assisted reproduction because in patients with ovarian failure, offering the same opportunity to female without ovarian alterations to increase the rate of pregnancies. MATERIAL AND METHOD: 98 donor's procedures were included in host patients; 87 were FIV-TE and 11 GIFT between march to june 1997. The patients were divided in age group: 1) < 30 years, 2) 30 to 34 years, 3) 35 to 39 years, 4) > or = 40 years. The donors were divided in known (26) and unknown (72). The results were analysed. RESULTS: 48 pregnancies (55.17%) of the 87 FIV-TE-D group were obtained with 31 neonates The implantation rate was 17.5% to FIV-TE group and 13.8 to GIFT group, 44 (61.11%) pregnancies were from unknown donors group and 9 (34.61%) from known donors group. CONCLUSIONS: Our results are similar to others international reports, we have observed a little and significative difference between pregnancy with oocytes from known donors and unknown donors; this is the principal motive to be selective in the suitable known donor.

Adjuvant metoprolol improves efficacy of class I antiarrhythmic drugs in patients with inducible sustained monomorphic ventricular tachycardia.

Inducible ventricular tachycardia frequently persists despite solitary class I antiarrhythmic drug therapy. To determine the effect of metoprolol as adjuvant therapy, 19 patients with clinical ventricular tachycardia with baseline inducible sustained monomorphic ventricular tachycardia and persistently inducible ventricular tachycardia despite class I drugs were evaluated. Eight of 19 patients (42%) became noninducible when metoprolol was added to class I drug therapy. Sixteen of 19 patients (84%) were harder to induce or noninducible on a regimen of adjuvant metoprolol therapy. In evaluating the clinical characteristics of the 19 patients, no significant differences were found between patients who were persistently inducible and those rendered noninducible. In evaluating the electrophysiologic characteristics, the group eventually rendered noninducible had a significantly shorter baseline induced cycle length (259 +/- 27 vs 305 +/- 53 msec). Combination class I drug and metoprolol therapy significantly lengthened the ventricular effective refractory period in both groups compared with baseline. The long-term follow-up was excellent in all patients remaining on metoprolol in the noninducible group. Therefore adjuvant metoprolol therapy creates a significant improvement in a number of patients with persistently inducible ventricular tachycardia despite class I drug therapy.